Case-non-case studies: Principle, methods, bias and interpretation
- PMID: 30773344
- DOI: 10.1016/j.therap.2019.01.006
Case-non-case studies: Principle, methods, bias and interpretation
Abstract
Case-non-case studies are among the methods used to assess drug safety by analyzing the disproportionality of adverse drug reaction reports in pharmacovigilance databases. First used in the 1980s, the last few decades have seen a significant increase in the use of this study design. The principle of case-non-case studies is to compare the drug exposure of cases of an adverse reaction of interest with that of cases with other reported reactions and called "non-cases". Their results are presented in the form of reporting odds ratio (ROR), the interpretation of which makes it possible to highlight pharmacovigilance signals. This article describes the principle of case-non-case studies, the calculation method of the ROR and its confidence interval, the different analytical modalities and how to interpret its results with regard to the advantages and limitations of this type of study.
Keywords: Bias; Case–non-case studies; Disproportionality analysis; Pharmacoepidemiology; Pharmacovigilance; Reporting odds ratio.
Copyright © 2019 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.
Similar articles
-
[Case-non case studies: Principles, methods, bias and interpretation].Therapie. 2018 May-Jun;73(3):247-255. doi: 10.1016/j.therap.2017.08.006. Epub 2017 Oct 31. Therapie. 2018. PMID: 29174397 Review. French.
-
The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.Pharmacoepidemiol Drug Saf. 2016 Dec;25(12):1361-1367. doi: 10.1002/pds.4115. Epub 2016 Sep 30. Pharmacoepidemiol Drug Saf. 2016. PMID: 27686554
-
Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):989-92. doi: 10.1002/pds.3622. Epub 2014 Apr 15. Pharmacoepidemiol Drug Saf. 2014. PMID: 24737486
-
Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):962-70. doi: 10.1002/pds.3811. Epub 2015 Jun 11. Pharmacoepidemiol Drug Saf. 2015. PMID: 26095121
-
A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases.J Clin Epidemiol. 2021 Nov;139:191-198. doi: 10.1016/j.jclinepi.2021.07.014. Epub 2021 Jul 27. J Clin Epidemiol. 2021. PMID: 34329725
Cited by
-
Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level.Clin Pharmacol Ther. 2022 Mar;111(3):605-613. doi: 10.1002/cpt.2499. Epub 2021 Dec 27. Clin Pharmacol Ther. 2022. PMID: 34860360 Free PMC article.
-
A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.Drug Saf. 2020 Jul;43(7):657-660. doi: 10.1007/s40264-020-00955-y. Drug Saf. 2020. PMID: 32495148 Free PMC article.
-
Everyday Evaluation of Herb/Dietary Supplement-Drug Interaction: A Pilot Study.Medicines (Basel). 2023 Feb 28;10(3):20. doi: 10.3390/medicines10030020. Medicines (Basel). 2023. PMID: 36976309 Free PMC article.
-
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.Target Oncol. 2024 May;19(3):435-445. doi: 10.1007/s11523-024-01058-9. Epub 2024 May 2. Target Oncol. 2024. PMID: 38696126 Free PMC article.
-
Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance.Pharmaceuticals (Basel). 2024 Mar 11;17(3):364. doi: 10.3390/ph17030364. Pharmaceuticals (Basel). 2024. PMID: 38543150 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical